Arcturus Therapeutics Holdings Inc
ARCT12.265USD
-0.035-0.28%
Market hours （ET）Quotes delayed by 15 min
332.64MMarket Cap
LossP/E TTM
More Details of Arcturus Therapeutics Holdings Inc Company
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Company Info
Ticker SymbolARCT
Company nameArcturus Therapeutics Holdings Inc
IPO dateMay 22, 2013
CEOMr. Joseph E. Payne
Number of employees174
Security typeOrdinary Share
Fiscal year-endMay 22
Address10628 Science Center Dr Ste 250
CitySAN DIEGO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92121-1132
Phone18589002660
Websitehttps://arcturusrx.com/
Ticker SymbolARCT
IPO dateMay 22, 2013
CEOMr. Joseph E. Payne
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
43.62%
Investment Advisor
28.78%
Hedge Fund
13.66%
Individual Investor
7.88%
Research Firm
5.21%
Insurance Company
1.01%
Pension Fund
0.52%
Bank and Trust
0.30%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
391
27.00M
99.57%
-3.36M
2025Q1
403
27.75M
102.37%
-3.11M
2024Q4
400
27.43M
101.26%
-2.26M
2024Q3
404
26.95M
99.66%
-3.33M
2024Q2
409
27.79M
102.77%
-2.68M
2024Q1
391
28.99M
107.82%
+144.88K
2023Q4
376
27.09M
101.05%
-1.26M
2023Q3
373
26.77M
100.23%
-170.02K
2023Q2
355
26.49M
99.74%
-2.09M
2023Q1
361
26.10M
98.32%
-2.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
4.69M
17.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
7.82%
-29.89K
-1.39%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
1.93M
7.1%
-138.97K
-6.73%
Mar 31, 2025
The Vanguard Group, Inc.
1.74M
6.43%
+64.37K
+3.83%
Mar 31, 2025
ARK Investment Management LLC
2.01M
7.41%
+74.63K
+3.86%
Mar 31, 2025
Payne (Joseph E)
1.48M
5.46%
--
--
Apr 08, 2025
State Street Global Advisors (US)
1.28M
4.72%
-45.71K
-3.45%
Mar 31, 2025
Balyasny Asset Management LP
938.19K
3.46%
+389.43K
+70.97%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
825.77K
3.04%
-23.32K
-2.75%
Mar 31, 2025
Woodline Partners LP
780.44K
2.88%
-26.47K
-3.28%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
2.14%
WisdomTree BioRevolution Fund
1.67%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
iShares Genomics Immunology and Healthcare ETF
0.74%
AXS Green Alpha ETF
0.54%
Global X Genomics & Biotechnology ETF
0.41%
ALPS Medical Breakthroughs ETF
0.24%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
View more
ARK Genomic Revolution ETF
Proportion2.14%
WisdomTree BioRevolution Fund
Proportion1.67%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.93%
iShares Genomics Immunology and Healthcare ETF
Proportion0.74%
AXS Green Alpha ETF
Proportion0.54%
Global X Genomics & Biotechnology ETF
Proportion0.41%
ALPS Medical Breakthroughs ETF
Proportion0.24%
SPDR S&P Biotech ETF
Proportion0.12%
iShares Micro-Cap ETF
Proportion0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
